(R)-Sulforaphane
Based on 2 publication(s) in Google Scholar
(R)-Sulforaphane (L-Sulforaphane) is a orally active, potent inducer of the Keap1/Nrf2/ARE pathway, exhibiting antioxidant and anticancer activities. (R)-Sulforaphane primarily functions by upregulating phase II detoxifying enzymes in cells, aiding in the removal of carcinogens and combating oxidative stress. (R)-Sulforaphane is capable of modulating gene expression, influencing various signaling pathways, including Nrf2, NF-κB, and AP-1. (R)-Sulforaphane can be used in studies of tumor biology, antioxidant defense mechanisms, as well as inflammation and immune responses.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.97%
- CAS No.: 142825-10-3
- Formule: C6H11NOS2
- Masse moléculaire:177.29
-
Stockage:
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-17363
Dimethyl fumarateNrf2 Activator -
HY-12212
OmaveloxoloneNrf2 Activator -
HY-19734
NK-252Nrf2 Activator -
HY-100523
ML385Nrf2 Inhibitor -
HY-16561
ResveratrolPolyphenolic Phytoalexin -
HY-10432
A 83-01ALK4/5/7 Inhibitor -
HY-13902
BerzosertibATR Inhibitor -
HY-10162
OlaparibPARP Inhibitor -
HY-B0240
DisulfiramALDH1 Inhibitor -
HY-15772
OsimertinibMutant-Selective EGFR Inhibitor -
HY-12028
PD98059MEK Inhibitor -
HY-13755
SulforaphaneKeap1/Nrf2/ARE Inducer
Publications Citing Use of MedChemExpress (MCE) (R)-Sulforaphane
MoreVoir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
Description
IC50 & Target
|
Bax |
Procaspase-3 |
NF-κB |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
19.6 μM
Compound: 2-RS
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25299679] |
| MRC5 | IC50 |
46.58 μM
Compound: 2-RS
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25299679] |
In Vitro
(R)-Sulforaphane (10 μM, 24 hours) pre-treatment of H9c2 cells reduces the number of apoptotic cells, decreases the expression of pro-apoptotic proteins (Bax, caspase-3, cytochrome c), and counteracts the increase in mitochondrial membrane potential induced by Doxorubicin (HY-15142A) (1 μM, 2 hours)[4].
(R)-Sulforaphane (10 μM, 2 or 24 hours) pre-treatment enhances the expression of HO-1 in H9c2 cells and reduces the levels of ROS within the mitochondria (measured using MitoSOX Red reagent) induced by Doxorubicin (1 μM, 2 or 24 hours)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF7 cells
-
Concentration:20 μM
-
Incubation Time:72h
-
Result:Increased the most the NQO1 transcript and protein levels in MCF7 cells.
Increased of Nrf2 transcript was observed in MCF7 cells.
Reduced transcription and protein of AhR gene in MCF7 cells.
-
Cell Line:H9c2 cells
-
Concentration:L-sulforaphane or D,L-sulforaphane: 10 μM; Doxorubicin: 1 μM
-
Incubation Time:L-sulforaphane or D,L-sulforaphane: 2h; Doxorubicin: 2, 24h
-
Result:Protected the H9c2 cells against doxorubicin-induced cell death.
Increased cell viability in a dose-dependent manner.
Significantly reduced the number of apoptotic cells treated with Doxorubicin.
-
Cell Line:H9c2 cells
-
Concentration:L-sulforaphane or D,L-sulforaphane: 10 μM; Doxorubicin: 1 μM
-
Incubation Time:L-sulforaphane or D,L-sulforaphane: 2h, 24h; Doxorubicin: 2h, 24h
-
Result:Induced heme oxygenase-1 (HO-1) mRNA expression in a dose-dependent manner.
-
Cell Line:H9c2 cells
-
Concentration:L-sulforaphane or D,L-sulforaphane: 10 μM; Doxorubicin: 1 μM
-
Incubation Time:L-sulforaphane or D,L-sulforaphane: 2h; Doxorubicin: 2, 24h
-
Result:Prevented the release of cytochrome c into the cytosol.
Prevented the translocation of Bax into the cytosol.
Attenuated the doxorubicin-induced increase in the levels of cleaved caspase-3.
Induced a significant increase in HO-1 protein expression.
Induced a significantly higher level of Nrf2 expression in the nucleus compared to the cytoplasm.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 142825-10-3
-
Appearance Liquid (Density: 1.17±0.1 g/cm3)
-
Masse moléculaire 177.29
-
Formule C6H11NOS2
-
Color Colorless to light yellow
-
SMILES
O=[S@@](CCCCN=C=S)C
-
Synonyms
L-Sulforaphane
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
2025 Oct:86:103837. PMID: 40857932 -
Antioxidants (Basel)
Aspirin Eugenol Ester Alleviates Gastric Injury by Inhibiting Ferroptosis and Oxidative Stress. [Abstract]2026 Feb 9;15(2):225. PMID: 41750606
Solvant et solubilité
In Vitro:
Ethanol : ≥ 100 mg/mL (564.05 mM)
DMSO : 100 mg/mL (564.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (645 KB)
- English - EN (645 KB)
- Français - FR (645 KB)
- Deutsch - DE (645 KB)
- Norwegian - NO (645 KB)
- Español - ES (645 KB)
- Swedish - SV (645 KB)
- Italian - IT (645 KB)
- Korean - KR (645 KB)
- Portuguese - PT (645 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. De Nicola GR, et al. Novel gram-scale production of enantiopure R-sulforaphane from Tuscan black kale seeds. Molecules. 2014 May 27;19(6):6975-86. [Content Brief]
[2]. Abdull Razis AF, et al. The natural chemopreventive phytochemical R-sulforaphane is a far more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer. Int J Cancer. 2011 Jun 15;128(12):2775-82. [Content Brief]
[3]. Gamet-Payrastre L, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000;60(5):1426-1433. [Content Brief]
[4]. Li B, et al. Sulforaphane prevents doxorubicin-induced oxidative stress and cell death in rat H9c2 cells. Int J Mol Med. 2015 Jul;36(1):53-64. doi: 10.3892/ijmm.2015.2199. Epub 2015 Apr 28. [Content Brief]
[5]. Licznerska B, et al. R-sulforaphane modulates the expression profile of AhR, ERα, Nrf2, NQO1, and GSTP in human breast cell lines. Mol Cell Biochem. 2021;476(2):525-533. [Content Brief]
[6]. Zhang Y, et al. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornylisothiocyanates. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3147-50. [Content Brief]
[7]. Chen X, et al. Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of PancreaticCancer via AMPK Dependent Signaling. ell Physiol Biochem. 2018;50(3):1201-1215. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 5.6405 mL | 28.2024 mL | 56.4048 mL | 141.0119 mL |
| 5 mM | 1.1281 mL | 5.6405 mL | 11.2810 mL | 28.2024 mL | |
| 10 mM | 0.5640 mL | 2.8202 mL | 5.6405 mL | 14.1012 mL | |
| 15 mM | 0.3760 mL | 1.8802 mL | 3.7603 mL | 9.4008 mL | |
| 20 mM | 0.2820 mL | 1.4101 mL | 2.8202 mL | 7.0506 mL | |
| 25 mM | 0.2256 mL | 1.1281 mL | 2.2562 mL | 5.6405 mL | |
| 30 mM | 0.1880 mL | 0.9401 mL | 1.8802 mL | 4.7004 mL | |
| 40 mM | 0.1410 mL | 0.7051 mL | 1.4101 mL | 3.5253 mL | |
| 50 mM | 0.1128 mL | 0.5640 mL | 1.1281 mL | 2.8202 mL | |
| 60 mM | 0.0940 mL | 0.4700 mL | 0.9401 mL | 2.3502 mL | |
| 80 mM | 0.0705 mL | 0.3525 mL | 0.7051 mL | 1.7626 mL | |
| 100 mM | 0.0564 mL | 0.2820 mL | 0.5640 mL | 1.4101 mL |
(R)-Sulforaphane Related Classifications
HY-13755A Related Classifications
Powered by Bioz